Evidence map›Paper›PMID 41479997›Full record

ReviewWorld journal of cardiology2025

Complex interrelationship and therapeutic advances in diabetic patients with atrial fibrillation.

Aikaterini-Eleftheria Karanikola, Dimitrios Tsiachris, Nikos Argyriou, Michail Botis, Konstantinos Pamporis, Panagiotis Xydis, Christos Fragoulis, Athanasios Kordalis, Konstantinos Tsioufis

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aikaterini-Eleftheria KaranikolaFirst Department of Cardiology, National and Kapodistrian University of Athens, "Hippokration" General Hospital, Athens 11527, Greece.
Dimitrios TsiachrisFirst Department of Cardiology, National and Kapodistrian University of Athens, "Hippokration" General Hospital, Athens 11527, Greece. dtsiachris@yahoo.com.
Nikos ArgyriouFirst Department of Cardiology, National and Kapodistrian University of Athens, "Hippokration" General Hospital, Athens 11527, Greece.
Michail BotisFirst Department of Cardiology, National and Kapodistrian University of Athens, "Hippokration" General Hospital, Athens 11527, Greece.
Konstantinos PamporisFirst Department of Cardiology, National and Kapodistrian University of Athens, "Hippokration" General Hospital, Athens 11527, Greece.
Panagiotis XydisFirst Department of Cardiology, National and Kapodistrian University of Athens, "Hippokration" General Hospital, Athens 11527, Greece.
Christos FragoulisFirst Department of Cardiology, National and Kapodistrian University of Athens, "Hippokration" General Hospital, Athens 11527, Greece.
Athanasios KordalisFirst Department of Cardiology, National and Kapodistrian University of Athens, "Hippokration" General Hospital, Athens 11527, Greece.
Konstantinos TsioufisFirst Department of Cardiology, National and Kapodistrian University of Athens, "Hippokration" General Hospital, Athens 11527, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus and atrial fibrillation (AF) are two global epidemics that frequently coexist, with diabetes mellitus contributing to both an increased risk of new-onset AF and a worse prognosis. Pathophysiological mechanisms underlying this relationship include chronic inflammation, oxidative stress, atrial remodeling, autonomic dysfunction, advanced glycation end-products and epicardial adiposity. Management remains challenging; however, recent advances offer promise, including guideline-directed anticoagulation, tailored rate and rhythm control, and particularly, novel antidiabetic therapies, such as sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, may improve AF outcomes. A comprehensive, individualized approach is essential to mitigate morbidity and mortality in this high-risk population.

Indexed as

ArrhythmiaAtrial fibrillationAtrial remodelingDiabetes mellitusManagementPathophysiology

Identifiers

PMID41479997
PMCPMC12754075

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.